Patents by Inventor James C. Marsters

James C. Marsters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAZOLE INHIBITORS OF WNT SIGNALING
    Publication number: 20100137394
    Abstract: The invention provides inhibitors of Wnt signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein R1 to R7 and Z are as defined herein.
    Type: Application
    Filed: April 29, 2008
    Publication date: June 3, 2010
    Applicants: Grenentech, Inc., Curis, Inc.
    Inventors: Shirley Ann Brunton, Janet L. Gunzner, Tom Coulter, John H.A Stibbard, James C. Marsters, JR.
  • LFA-1 antagonist compounds
    Patent number: 6872735
    Abstract: The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: March 29, 2005
    Assignee: Genentech, Inc.
    Inventors: Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, James C. Marsters
  • LFA-1 antagonist compounds
    Publication number: 20040058968
    Abstract: The invention relates to novel compounds having formula (I) 1
    Type: Application
    Filed: July 11, 2003
    Publication date: March 25, 2004
    Applicant: Genentech, Inc.
    Inventors: Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, James C. Marsters
  • LFA-1 antagonist compounds
    Patent number: 6667318
    Abstract: The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.
    Type: Grant
    Filed: November 26, 2001
    Date of Patent: December 23, 2003
    Assignee: Genentech, Inc.
    Inventors: Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, James C. Marsters
  • Compositions and methods for detecting and quantifying gene expression
    Publication number: 20030190660
    Abstract: Compositions and methods for improving detection sensitivity in nucleic acid microarray analysis are disclosed, including methods of purifying nucleic acids, methods of synthesizing fluorescent DNA probes, methods of hybridization, and methods of activating a substrate for target molecule attachment are disclosed.
    Type: Application
    Filed: April 2, 2003
    Publication date: October 9, 2003
    Applicant: Genentech, Inc.
    Inventors: David G. Lowe, James C. Marsters, Edward P. Robbie, Victoria Smith
  • LFA-1 Antagonist compounds
    Publication number: 20020119994
    Abstract: The invention relates to novel compounds having formula (I) 1
    Type: Application
    Filed: November 26, 2001
    Publication date: August 29, 2002
    Applicant: GENENTECH, INC
    Inventors: Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, James C. Marsters
  • Compositions and methods for detecting and quantifying gene expression
    Publication number: 20020081597
    Abstract: Compositions and methods for improving detection sensitivity in nucleic acid microarray analysis are disclosed, including methods of purifying nucleic acids, methods of synthesizing fluorescent DNA probes, methods of hybridization, and methods of activating a substrate for target molecule attachment are disclosed.
    Type: Application
    Filed: March 30, 2001
    Publication date: June 27, 2002
    Applicant: GENENTECH, INC.
    Inventors: David G. Lowe, James C. Marsters, Edward P. Robbie, Victoria Smith
  • Ras farnesyl transferase inhibitors
    Patent number: 5843941
    Abstract: Benzodiazepine derivatives represented by the structure below are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases foe which inhibition of the ras farnesyl:protein transferase as indicated.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: December 1, 1998
    Assignees: Genentech, Inc., Board of Regents University of Texas
    Inventors: James C. Marsters, Jr., Michael S. Brown, Craig W. Crowley, Joseph L. Goldstein, Guy L. James, Robert S. McDowell, David Oare, Thomas E. Rawson, Mark Reynolds, Todd C. Somers
  • Ras farnesyl transferase inhibitors
    Patent number: 5532359
    Abstract: Benzodiazepine derivatives are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases for which inhibition of the ras farnesyl:protein transferase is indicated.
    Type: Grant
    Filed: October 25, 1994
    Date of Patent: July 2, 1996
    Assignees: Genentech, Inc., Board of Regents, The University of Texas System
    Inventors: James C. Marsters, Jr., Michael S. Brown, Craig W. Crowley, Joseph L. Goldstein, Guy L. James, Robert S. McDowell, David Oare, Thomas E. Rawson, Mark Reynolds, Todd C. Somers